Revenues (Details) € in Thousands, $ in Thousands, $ in Thousands |
1 Months Ended | 12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Oct. 31, 2025
USD ($)
|
Jun. 28, 2021 |
Mar. 16, 2021
USD ($)
|
Jul. 31, 2019
USD ($)
|
Mar. 31, 2015
USD ($)
|
Mar. 31, 2015
CAD ($)
|
Dec. 31, 2025
USD ($)
|
Dec. 31, 2025
EUR (€)
|
Sep. 24, 2024
USD ($)
|
Apr. 06, 2018
USD ($)
|
|
| Revenues [Line Items] | ||||||||||
| Additional payment | $ 2,000 | |||||||||
| Net sales percentage | 16.50% | 16.50% | ||||||||
| Transfer price rate | 10.00% | |||||||||
| Terms of agreement | $ 750 | |||||||||
| Additional achieved milestone | $ 40,450 | 3,250 | ||||||||
| Revenues recognized | $ 2,000 | |||||||||
| Non-refundable payment | $ 2,250 | € 250 | ||||||||
| Milestone payment percentage | 30.00% | 30.00% | ||||||||
| Finite-lived patents, gross | $ 250 | |||||||||
| Maximum [Member] | ||||||||||
| Revenues [Line Items] | ||||||||||
| Percentage of royalties on net sales | 40.00% | |||||||||
| Minimum [Member] | ||||||||||
| Revenues [Line Items] | ||||||||||
| Percentage of royalties on net sales | 15.00% | |||||||||
| Cipher Pharmaceuticals [Member] | ||||||||||
| Revenues [Line Items] | ||||||||||
| Upfront payment | $ 1,292 | $ 1,650 | ||||||||
| Chong Kun Dang Pharmaceuticals Corp. [Member] | ||||||||||
| Revenues [Line Items] | ||||||||||
| Terms of agreement | $ 1,500 | |||||||||
| Additional achieved milestone | 500 | |||||||||
| Gebro Holding GmbH [Member] | ||||||||||
| Revenues [Line Items] | ||||||||||
| Terms of agreement | 1,850 | € 1,500 | ||||||||
| Additional achieved milestone | $ 720 | € 600 | ||||||||
| Description of additional payments | Under the Distribution and Supply Agreement, the Company is entitled to € 1,500 thousands upon execution of the agreement. In addition, the Company is also entitled to milestone payments upon achieving certain clinical, launch and sales milestones, as follows: (i) € 300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and € 300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between € 750 thousand and € 1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between € 300 thousand and up to €4,025 thousand upon meeting certain net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson. | Under the Distribution and Supply Agreement, the Company is entitled to € 1,500 thousands upon execution of the agreement. In addition, the Company is also entitled to milestone payments upon achieving certain clinical, launch and sales milestones, as follows: (i) € 300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and € 300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between € 750 thousand and € 1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between € 300 thousand and up to €4,025 thousand upon meeting certain net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson. | ||||||||
| Vetbiolix [Member] | ||||||||||
| Revenues [Line Items] | ||||||||||
| Description of additional payments | On August 6, 2018, the Company entered into a License, Collaboration and Distribution Agreement with CMS Medical Venture Investment Limited (“CMS Medical”) for the commercialization of Piclidenoson for the treatment of rheumatoid arthritis, psoriasis and Namodenoson for the treatment of advanced liver cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan). | On August 6, 2018, the Company entered into a License, Collaboration and Distribution Agreement with CMS Medical Venture Investment Limited (“CMS Medical”) for the commercialization of Piclidenoson for the treatment of rheumatoid arthritis, psoriasis and Namodenoson for the treatment of advanced liver cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan). | ||||||||
| Revenues recognized | $ 271 | |||||||||
| CMS Medical Venture Investment Limited [Member] | ||||||||||
| Revenues [Line Items] | ||||||||||
| Upfront and milestone payments payable | $ 2,000 | |||||||||
| Regulatory Milestones [Member] | ||||||||||
| Revenues [Line Items] | ||||||||||
| Additional achieved milestone | $ 14,000 | |||||||||
| Sales Milestones [Member] | ||||||||||
| Revenues [Line Items] | ||||||||||
| Additional achieved milestone | 58,500 | |||||||||
| Kyongbo Pharm Co Ltd [Member] | ||||||||||
| Revenues [Line Items] | ||||||||||
| Revenues recognized | $ 750 | |||||||||
| Ewopharma [Member] | ||||||||||
| Revenues [Line Items] | ||||||||||
| Terms of agreement | $ 2,250 | |||||||||
| Percentage of royalties on net sales | 17.50% | |||||||||
| South Korea [Member] | ||||||||||
| Revenues [Line Items] | ||||||||||
| Net sales percentage | 23.00% | |||||||||
| Liver Cancer Indication [Member] | ||||||||||
| Revenues [Line Items] | ||||||||||
| Upfront and milestone payments payable | $ 3,000 | |||||||||
| NASH [Member] | ||||||||||
| Revenues [Line Items] | ||||||||||
| Upfront and milestone payments payable | $ 6,000 | |||||||||